In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to detect Protected dosing routine. Additional individuals are going to be enrolled on the determined monotherapy dosign program. In Phase B, participants will acquire oral ruxolitinib and ABBV-744 will probably be supplied as "add-on" therapy. In https://damienwhsdo.theisblog.com/32248481/the-best-side-of-abbv-744-clinical-trial-phase-1-results